Citations

Clear

634 citation(s) found for "Hall, A".

Clinical and Laboratory Features of Mycobacterium mageritense
Wallace, Richard J. , Brown‐Elliott, Barbara A. , Hall, Leslie, Roberts, Glenn D., Wilson, Rebecca W., Mann, Linda, Crist, Christopher J., Chiu, Sher H., Dunlap, Robbie, Bagwell, J. Todd, Jost, Kenneth, García, María Jesús García

Mayo Clinic

Journal of Clinical Microbiology | October 1, 2002 | Volume: 40 | Issue: 8 | Pages: 2930-2935

10.1128/jcm.40.8.2930-2935.2002 | PMID 12149354 Get It

ABSTRACT Six clinical isolates of the nonpigmented, rapidly growing species Mycobacterium mageritense were recovered from sputum, bronchial wash, blood, sinus drainage, and two surgical wound infections from separate patients in Texas, New York, Louisiana, and Florida. The isolates matched the ATCC type strain by PCR restriction enzyme analysis of the 65-kDa hsp gene sequence of Telenti, high-performance liquid chromatography, biochemical reactions, and partial 16S rRNA gene sequencing. These are the first isolates of this species to be described in the United States and the first isolates to be associated with clinical disease. Susceptibility testing of all known isolates of the species revealed all isolates to be susceptible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones and sulfonamides but resistant to clarithromycin. Because of their phenotypic and clinical similarity to isolates of the Mycobacterium fortuitum third biovariant complex (sorbitol positive), isolates of M. mageritense are likely to go undetected unless selected carbohydrate utilization or molecular identification methods are used.
Oxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Bulatović, Vanja M., Wengenack, Nancy L. , Uhl, James R., Hall, Leslie, Roberts, Glenn D., Cockerill, Franklin R., Rusnak, Frank

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 1, 2002 | Volume: 46 | Issue: 9 | Pages: 2765-2771

10.1128/aac.46.9.2765-2771.2002 | PMID 12183226 Get It

ABSTRACT Isoniazid is a first-line antibiotic used in the treatment of infections caused by Mycobacterium tuberculosis . Isoniazid is a prodrug requiring oxidative activation by the catalase-peroxidase hemoprotein, KatG. Resistance to isoniazid can be obtained by point mutations in the katG gene, with one of the most common being a threonine-for-serine substitution at position 315 (S315T). The S315T mutation is found in more than 50% of isoniazid-resistant clinical isolates and results in an ≈200-fold increase in the MIC of isoniazid compared to that for M. tuberculosis H37Rv. In the present study we investigated the hypothesis that superoxide plays a role in KatG-mediated isoniazid activation. Plumbagin and clofazimine, compounds capable of generating superoxide anion, resulted in a lower MIC of isoniazid for M. tuberculosis H37Rv and a strain carrying the S315T mutation. These agents did not cause as great of an increase in isoniazid susceptibility in the mutant strain when the susceptibilities were assessed by using the inhibitory concentration that causes a 50% decrease in growth. These results provide evidence that superoxide can play a role in isoniazid activation. Since clofazimine alone has antitubercular activity, the observation of synergism between clofazimine and isoniazid raises the interesting possibility of using both drugs in combination to treat M. tuberculosis infections.
Mycobacterium triplex Infection in a Liver Transplant Patient
Hoff, Elsebeth, Sholtis, Mary, Procop, Gary W. , Sabella, Camille, Goldfarb, Johanna , Wyllie, Robert , Cunningham, Ronan, Stockman, L, Hall, Gerri S.

Mayo Clinic

Journal of Clinical Microbiology | July 27, 2002 | Volume: 39 | Issue: 5 | Pages: 2033-2034

10.1128/jcm.39.5.2033-2034.2001 | PMID 11326044 Get It

ABSTRACT Mycobacterium triplex was first named in 1996 as an acid-fast bacillus with features that most resemble Mycobacterium simiae and Mycobacterium avium-intracellulare complex but which possesses a distinct mycolic acid pattern as well as a distinctive 16S rRNA hypervariable region. It has been isolated from lymph node, sputum, and cerebrospinal fluid specimens, but to date only rare clinical cases of this organism have been reported in the literature. The following is a case report of M. triplex that was isolated from the pericardial and peritoneal fluid of a 13-year-old female liver transplant patient.
Evaluation of ColorPAC Giardia/Cryptosporidium Rapid Assay and ProSpecT Giardia/Cryptosporidium Microplate Assay for Detection of Giardia and Crypto
Katanik, M. T., Schneider, Susan K., Rosenblatt, Jon E., Hall, Geraldine S., Procop, Gary W.

Mayo Clinic

Journal of Clinical Microbiology | July 27, 2002 | Volume: 39 | Issue: 12 | Pages: 4523-4525

10.1128/jcm.39.12.4523-4525.2001 | PMID 11724874 Get It

ABSTRACT Detection of Giardia and Cryptosporidium in clinical stool specimens using the ColorPAC and ProSpecT enzyme immunoassays revealed 98.7% agreement for Giardia detection and 98.1% agreement for Cryptosporidium detection. Sensitivities were uniformly 100%. The specificities of the ColorPAC immunoassay for Giardia and Cryptosporidium detection were 100 and 99.5%, respectively, and those for the ProSpecT assay were 98.4 and 98.6%, respectively. The false-positive reactions with the ProSpecT assay occurred with specimens that were grossly bloody.